Alexandra M Gaynor1,2,3, Anam Ahsan4, Duane Jung5, Elizabeth Schofield4, Yuelin Li4, Elizabeth Ryan4, Tim A Ahles4, James C Root4. 1. Department of Psychiatry and Behavioral Sciences, Neurocognitive Research Laboratory, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave., 7thFloor, New York, NY, 10022, USA. ag4498@cumc.columbia.edu. 2. Taub Institute for Research On Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA. ag4498@cumc.columbia.edu. 3. Cognitive Neuroscience Division, Department of Neurology, Columbia University, New York, NY, USA. ag4498@cumc.columbia.edu. 4. Department of Psychiatry and Behavioral Sciences, Neurocognitive Research Laboratory, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave., 7thFloor, New York, NY, 10022, USA. 5. Enformia Inc, Davidson, NC, USA.
Abstract
PURPOSE: There is increasing interest in developing new methods to improve sensitivity in detecting subtle cognitive deficits associated with cancer and its treatments. The current study aimed to evaluate the ability of a novel computerized battery of cognitive neuroscience-based tests to discriminate between cognitive performance in breast cancer survivors and controls. METHODS: Breast cancer survivors (N = 174) and age-matched non-cancer controls (N = 183) completed the Enformia Cogsuite Battery of cognitive assessments, comprised of 7 computerized tests of multiple cognitive domains. Primary outcome measures included accuracy, reaction times (RT), and coefficients of variation (CV) for each task, as well as global scores of accuracy, RT, and CV aggregated across tests. RESULTS: Linear regressions adjusting for age, education, and remote vs. in-office administration showed that compared to non-cancer controls, survivors had significantly lower performance on measures of attention, executive function, working memory, verbal ability, visuospatial ability, and motor function. Survivors had significantly greater CV on measures of attention, working memory, and processing speed, and significantly slower RT on measures of verbal fluency. CONCLUSIONS: The Cogsuite battery demonstrates sensitivity to cancer-related cognitive dysfunction across multiple domains, and is capable of identifying specific cognitive processes that may be affected in survivors. IMPLICATIONS FOR CANCER SURVIVORS: The sensitivity of these tasks to subtle cognitive deficits has advantages for initial diagnosis of cancer-related cognitive dysfunction, as well as detecting changes in survivors' cognitive function over time. The remote delivery of the battery may help overcome barriers associated with in-office administration and increase access to neurocognitive evaluation.
PURPOSE: There is increasing interest in developing new methods to improve sensitivity in detecting subtle cognitive deficits associated with cancer and its treatments. The current study aimed to evaluate the ability of a novel computerized battery of cognitive neuroscience-based tests to discriminate between cognitive performance in breast cancer survivors and controls. METHODS: Breast cancer survivors (N = 174) and age-matched non-cancer controls (N = 183) completed the Enformia Cogsuite Battery of cognitive assessments, comprised of 7 computerized tests of multiple cognitive domains. Primary outcome measures included accuracy, reaction times (RT), and coefficients of variation (CV) for each task, as well as global scores of accuracy, RT, and CV aggregated across tests. RESULTS: Linear regressions adjusting for age, education, and remote vs. in-office administration showed that compared to non-cancer controls, survivors had significantly lower performance on measures of attention, executive function, working memory, verbal ability, visuospatial ability, and motor function. Survivors had significantly greater CV on measures of attention, working memory, and processing speed, and significantly slower RT on measures of verbal fluency. CONCLUSIONS: The Cogsuite battery demonstrates sensitivity to cancer-related cognitive dysfunction across multiple domains, and is capable of identifying specific cognitive processes that may be affected in survivors. IMPLICATIONS FOR CANCER SURVIVORS: The sensitivity of these tasks to subtle cognitive deficits has advantages for initial diagnosis of cancer-related cognitive dysfunction, as well as detecting changes in survivors' cognitive function over time. The remote delivery of the battery may help overcome barriers associated with in-office administration and increase access to neurocognitive evaluation.
Authors: Heleen E M Feenstra; Jaap M J Murre; Ivar E Vermeulen; Jacobien M Kieffer; Sanne B Schagen Journal: J Clin Exp Neuropsychol Date: 2017-07-03 Impact factor: 2.475
Authors: Andrew M Heitzer; Jason M Ashford; Brian T Harel; Adrian Schembri; Michelle A Swain; Joanna Wallace; Kirsten K Ness; Fang Wang; Hui Zhang; Thomas E Merchant; Giles W Robinson; Amar Gajjar; Heather M Conklin Journal: J Neurooncol Date: 2018-11-22 Impact factor: 4.130
Authors: James C Root; Elizabeth Ryan; Gregory Barnett; Charissa Andreotti; Kemi Bolutayo; Tim Ahles Journal: Psychooncology Date: 2014-07-05 Impact factor: 3.894
Authors: Frederick Verbruggen; Adam R Aron; Guido Ph Band; Christian Beste; Patrick G Bissett; Adam T Brockett; Joshua W Brown; Samuel R Chamberlain; Christopher D Chambers; Hans Colonius; Lorenza S Colzato; Brian D Corneil; James P Coxon; Annie Dupuis; Dawn M Eagle; Hugh Garavan; Ian Greenhouse; Andrew Heathcote; René J Huster; Sara Jahfari; J Leon Kenemans; Inge Leunissen; Chiang-Shan R Li; Gordon D Logan; Dora Matzke; Sharon Morein-Zamir; Aditya Murthy; Martin Paré; Russell A Poldrack; K Richard Ridderinkhof; Trevor W Robbins; Matthew Roesch; Katya Rubia; Russell J Schachar; Jeffrey D Schall; Ann-Kathrin Stock; Nicole C Swann; Katharine N Thakkar; Maurits W van der Molen; Luc Vermeylen; Matthijs Vink; Jan R Wessel; Robert Whelan; Bram B Zandbelt; C Nico Boehler Journal: Elife Date: 2019-04-29 Impact factor: 8.140